Diosmetin Exerts Synergistic Effects in Combination with 5-Fluorouracil in Colorectal Cancer Cells

Abstract

5-Fluorouracil (5-FU) is a chemotherapeutic medication commonly used to treat colorectal cancer (CRC); however, the drug-associated adverse effects and toxicity have greatly affected its clinical use. Exploring another therapeutic strategy that lowers the toxicity of 5-FU while having a synergistic effect against CRC is thus a viable option. Diosmetin, a natural flavonoid, has been shown to inhibit the proliferation of many cancer cells, including CRC cells. This study aims to investigate the synergistic effect of diosmetin and 5-FU on HCT116 and HT29 colorectal cancer cells and to explore the apoptotic activity of this combination. The MTT assay was used to assess the viability of cells treated with monotherapy and combination therapy. The combination index (CI) and dose reduction index (DRI) were calculated using the CompuSyn software (version 1.0). The SynergyFinder 2.0 software was used to calculate the synergy score, while the Combenefit software was employed to perform isobologram analysis and synergism determination. The AO/PI double staining technique was used to detect the apoptotic characteristics of cells, whereas the flow cytometry technique was used to investigate the apoptosis induction and cell cycle arrest in cells. The combination of 5-FU and diosmetin showed a synergistic effect in HCT116 cells with a mean CI value of 0.66 ± 0.4, and an additive effect in HT29 cells with a CI value of 1.0 ± 0.2. The DRI of 5-FU in HCT116 cells was three times lower in the combination therapy compared to monotherapy of 5-FU. AO/PI microscopic examination and Annexin V analysis revealed that the combination-treated cells had more apoptotic cells than the monotherapy-treated cells, which was activated mainly through intrinsic apoptosis pathway. HCT116 cell death was confirmed by mitotic arrest in the G2/M phase. Our findings suggest that 5-FU/diosmetin combination exhibits synergistic effect against HCT116 cancer cells, and potentially reduces the unfavorable adverse effect of 5-FU while enhancing the anticancer efficacy by inducing apoptosis and interrupting mitosis. Further research studies are needed to validate the combination’s anti-tumorigenic activities in a xenograft animal model.

A Synergistic pH-Responsive serum albumin-based drug delivery system loaded with doxorubicin and pentacyclic triterpene betulinic acid for potential treatment of NSCLC

“…The term combination therapy is used when two or more drugs positively affect the drugs' pharmacodynamics interaction (i.e., additive and synergistic). The primary purpose of combination therapy is to lower drug doses so that the patients experience less side effects while the efficiency of the treatment is enhanced [51]. In our experiments a synergistic effect is revealed in the drug combination of Dox and BeA increasing the cytotoxic effect.…”

Oxaliplatin-loaded nanoemulsion containingTeucrium poliumL. essential oil induces apoptosis in Colon cancer cell lines through ROS-mediated pathway

“…Treatment of HT-29 cells with the combined formulation comprising 0.3% (v/v) TPO-NANO and 0.3 µM Oxa resulted in lower clonogenic potential than cells treated with 0.3 µM Oxa-NS alone ( p ≥ 0.05). The higher reduction in colony formation in HCT116 cells after treatment with Oxa + TPO-NANO, relative to HT-29 cells, may be attributed to the combined effect of ROS-dependent Bax translocation and enhanced level of tumor suppressor p53 protein function in HCT116 cells, whereas HT-29 has a mutant-type p53 protein which enhanced the growth reduction independently via ROS-mediated to apoptosis of cancer cells (Arango et al., 2004 ; Dabiri et al., 2019 ; Kamran et al., 2022 ; Wu et al., 2019 ).…”

A Synergistic pH-Responsive Serum Albumin-Based Drug Delivery System Loaded with Doxorubicin and Pentacyclic Triterpene Betulinic Acid for Potential Treatment of NSCLC

“…The term combination therapy is used when two or more drugs positively affect the drugs’ pharmacodynamics interaction (i.e., additive and synergistic). The primary purpose of combination therapy is to lower drug doses so that the patients experience fewer side effects while the efficiency of the treatment is enhanced [ 59 ]. Furthermore, repurposing old drugs with new applications as a potential treatment for other diseases, such as lung cancer, is advantageous to the drug combination [ 60 ].…”